Our Businesses

The comprehensive healthcare business recorded a profit of HK$79.71 million during the year, accounting for approximately 2.2% of the Group's net profit. The company acquired 40% equity of Shanghai Pharmaceutical Group through a 50% stake joint venture company. Shanghai Pharmaceutical Group holds 19.348% of the A shares of Shanghai Pharmaceutical Co., Ltd., which is listed in Shanghai and Hong Kong, and is its single largest shareholder of A shares.